Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Use or lose may hit big drugs

Posted 22 February 2021 AM

The new time limit on taking up positive PBAC recommendations announced last week looms over a number of drugs presently stalled in the post-PBAC phase.

Under the new limit, the reimbursement committee will review positive recommendations "not accepted" by sponsors within two years. Sponsors will be forced to either confirm they have chosen not to proceed with the listing process (in which case the recommendation will be ceased) or request that the recommendation be retained, say why and give a date for when they intend to proceed with listing.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Does pharma have a man problem?
Survey adds to data on men's growing dissatisfaction
Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas